Prescribing and Formulary Panel

Minutes of meeting held on Tuesday November 5th 2019

The Oak MDT Room FKA The Old Board Room PEH

Members

Miss Geraldine O'Riordan, Prescribing Advisor and Chair (GOR)

Mrs Janine Clarke, Pharmacy Manager, HSC (JC)

Dr Julia Rebstein, Island Health Medical Practice (JR)

Dr Douglas Wilson, Queens Road Medical Practice (SW)

Dr Mike McCarthy, Healthcare Group (MMcC)

Dr Hamish Duncan, Medical Specialist Group (HD)

Dr Nikki Brink, Director of Public Health (NB)

Dr Peter Gomes, Medical Specialist Group (PG)

1: Absent/ Apologies for Absence

Dr Duncan (Apologies)

2: Minutes

The minutes of the October 2019 meeting were approved.

3: Additions to the Prescribing List

- **Nivolumab**

This product has been requested for a patient with advanced kidney cancer as per TA 417. The trial showed a mortality benefit of approximately 6 months extra of life compared with everolimus. The NHS discount is now available and, using the discounted price, the estimated cost per QUALY gained is likely to be just under the threshold approved for further consideration by the Panel. After a discussion it was recommended for approval as per the TA. GOR stated that, for all oncology drugs, each indication would now need to be reviewed individually. In the case of oral oncology drugs on the White List, the TA for which it is approved will be specified on the list in future.

Action : GOR

- **Evolocumab**

A decision regarding this product was deferred from the October meeting pending clarification of the pathway. This was received and answered members' questions. After a discussion it was agreed to recommend it for use by the FH clinic as per the TA and the guidelines.

Action : GOR

- **Burosumab**

This product is an ultra-orphan drug (a monoclonal antibody) for X-linked hypophosphataemic rickets (XLH). The very high price was noted: £700K per patient per year for the maximum dose (90mg every two weeks) at BNF list prices.

Two islanders have been diagnosed with the condition and were recommended the drug by a Great Ormond Street Consultant. It was noted that the discounted price was not yet known and that details of the administration requirements e.g. possible admission to hospital for the first doses, administration of all subsequent doses by a trained nurse and where this should take place, transport of the stock to Guernsey all had yet to be arranged. GOR said that she had exchanged several phone calls, emails and letters with GOSH and with the drug company and has had a number of teleconferences with the drug company. The company wants discuss the shared care arrangements between Guernsey and GOSH, where and by whom the drug will be initiated and administered. A confidentiality agreement will be required. These extra assurances are requested by the company because Guernsey is outside of the NHS.

After a discussion it was agreed to defer a decision until the above arrangements are in place. The family are aware of the delay.

Action : GOR

- **Paravit CF**

This product has been recommended by a Southampton Consultant for a Guernsey patient with cystic fibrosis to replace a number of different vitamin preparations. The cost of the new product is less than the combined cost of the products he is currently taken. After a discussion it was agreed to recommend this for approval.

Action : GOR

- **Orkambi**

This product has now been approved for use in the UK following a confidential financial agreement between Vertex and the NHS. GOR said that she contacted the company

immediately after the NHS agreement was announced. She had had several telephone and email exchanges with the company to ascertain the price before the meeting. A confidentiality agreement was prepared before the price could be released. At the request of HSC colleagues, this is currently with them for checking and to establish who the best signatory might be. It was noted that there are between three and five patients on the islands who will be suitable for the drug is approved. After a discussion it was agreed that a decision will be deferred until an indication of the cost is known.

Action: GOR

AOB

- **Ibrutinib :** the formulation will be changed from capsules to tablets and more strengths will be available. This cost-neutral change was approved.
- **Rituximab :** a change from IV to SC preparation will reduce administration time to the patient from 4 to 6 hours to 45 minutes and will slightly reduce preparation time in pharmacy. This was approved.
- **Circulation of papers to colleagues :** Members are reminded that it is important that papers are circulated to all of their colleagues in the prescribing organisations i.e. all GPs in the practices, all MSG Consultants and all States-employed Consultants for their awareness, comment and to obtain feedback on the recommendations.
- **Dates of December meeting :** this has been changed to December 3rd.

ACTION : GOR /ALL

6: Dates of next meeting : <u>Tuesday December 3rd 2019 at 5pm : new date</u>